Three years ago BioCryst Pharmaceuticals gave up on a drug it was developing to treat influenza.
The drug, peramivir, had failed in clinical trials, in part because not enough of it got into the bloodstream when taken orally. Johnson & Johnson pulled out of a partnership with BioCryst in 2001 when it saw that other flu drugs were not selling well.
